公开(公告)号：US20090012006A1

公开(公告)日：2009-01-08

申请号：US11576304

申请日：2005-09-30

Applicant: Mototsugu Kabeya ,  Kyoko Yasuoka ,  Toru Kanke ,  Hiroyuki Ishiwata ,  Junya Tagashira

Inventor： Mototsugu Kabeya ,  Kyoko Yasuoka ,  Toru Kanke ,  Hiroyuki Ishiwata ,  Junya Tagashira

IPC: A61K38/06 ,  C07K5/083 ,  A61P35/00 ,  A61P11/06

CPC classification number: C07K5/0827 ,  A61K38/00 ,  C07D209/14 ,  C07K5/0806 ,  C07K5/0812

Abstract: Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein R1 is hydrogen, halogeno, or a group represented by the general formula (2): (wherein R11 is straight-chain or branched C1-6 alkylene or the like; and R12 and R13 together with the nitrogen atom adjacent to them form a 5- to 7-membered ring); R2 is straight-chain or branched C1-6 alkyl or the like; R3 and R4 are each independently hydrogen, one to three halogen atoms, or the like; and A1-A2-A3 is a tripeptide residue composed of α-amino acids each independently selected from the group consisting of glycine, alanine, cyclohexylalanine, and so on.

Abstract translation: 由通式（1）表示的化合物或其盐或两者的溶剂合物; 含有这些化合物的PAR-2拮抗剂; 以及含有拮抗剂作为活性成分的PAR-2相关疾病的预防或治疗剂：（1）其中R1是氢，卤素或由通式（2）表示的基团：（其中R11是直链或支链的 C 1-6亚烷基等; R 12和R 13与它们相邻的氮原子一起形成5-至7-元环）; R2是直链或支链C 1-6烷基等; R3和R4各自独立地为氢，一至三个卤素原子等; 并且A1-A2-A3是由各自独立地选自甘氨酸，丙氨酸，环己基丙氨酸等的α-氨基酸组成的三肽残基。

公开(公告)号：US20080275081A1

公开(公告)日：2008-11-06

申请号：US12217708

申请日：2008-07-07

Applicant: Koji Oida

Inventor： Koji Oida

IPC: A61K31/47 ,  C07D215/00 ,  A61P31/04

CPC classification number: A61K31/00 ,  A61K31/47

Abstract: It is intended to provide a novel pharmaceutical effect of HMG-COA reductase inhibitors, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-di hydroxy-6-heptenoic acid or its salt. Namely, TM expression promoters, more specifically speaking, antithrombotic drugs, preventive/remedies for sepsis, antiplatelet drugs and anticoagulants comprising as the active ingredient an HMG-COA reductase inhibitor, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid or its salt.

Abstract translation: 旨在提供HMG-COA还原酶抑制剂，特别是（+） - （3R，5S，6E）-7- [2-环丙基-4-（4-氟苯基）-3-喹啉基] -3,5-二羟基-6-庚烯酸或其盐。 即，TM表达启动子，更具体地说是抗血栓药物，包含作为活性成分的HMG-COA还原酶抑制剂，特别是（+） - （3R，5S，6E） - 的抗疟药的预防/治疗，抗血小板药物和抗凝剂。 7- [2-环丙基-4-（4-氟苯基）-3-喹啉基] -3,5-二羟基-6-庚烯酸或其盐。

公开(公告)号：US07440035B2

公开(公告)日：2008-10-21

申请号：US10558524

申请日：2004-07-06

Applicant: Masafumi Mori

Inventor： Masafumi Mori

IPC: H04N9/475 ,  H04N5/00

CPC classification number: H04N9/68 ,  H04B3/36 ,  H04N7/102 ,  H04N9/641 ,  H04N11/00

Abstract: Attenuation compensation volume computing means (60, 61, 62, 63, 67, 68, 69, 70) of a signal receiver computes attenuation compensation volume of a video signal (GL, GH) on the basis of attenuation of pulses which are arranged in a digital sound signal LRD from the signal transmitter, and video signal attenuation compensation means (60, 61) of the signal receiver compensates the attenuation of the video signal (RAT, GAT, BAT) on the basis of the computed attenuation compensation volume (GL, GH), thereby stably compensating the attenuation of the video signal irrespective of kinds of displays or resolution of an image, and outputting good sounds to a video output machine as well as good videos.

Abstract translation: 信号接收器的衰减补偿量计算装置（60,61,62,63,67,68,69,70）计算视频信号（G L，G H）的衰减补偿量 基于从信号发送器排列在数字声音信号LR＆lt; D＆gt;中的脉冲的衰减，信号接收器的视频信号衰减补偿装置（60,61）补偿 基于所计算的衰减补偿量（G L ，G H），从而稳定地补偿视频信号的衰减，而与图像的种类或分辨率无关，并且向视频输出机输出良好的声音以及 好视频

公开(公告)号：US07419470B2

公开(公告)日：2008-09-02

申请号：US10473108

申请日：2002-03-29

Applicant: Akihiko Uchiyama ,  Kenji Yanashima ,  Sunao Takeda ,  Go Taguchi ,  Takuro Yokoyama

Inventor： Akihiko Uchiyama ,  Kenji Yanashima ,  Sunao Takeda ,  Go Taguchi ,  Takuro Yokoyama

IPC: A61B8/00 ,  A61B8/12 ,  A61B8/14

CPC classification number: A61B3/165 ,  A61B8/10

Abstract: An intraocular tension measuring method comprising vibrating an eyeball to be examined by a sound wave, measuring vibration of the eyeball to be examined by a noninvasive means to determine a Q value of resonance of the eyeball to be examined, and calculating intraocular tension from the Q value, and an intraocular tension measuring device comprising a vibrating means for vibrating an eyeball to be examined by a sound wave, a measuring means for noninvasively measuring vibration of the eyeball to be examined, a Q value calculating means for calculating a Q value of resonance of the eyeball to be examined from the vibration measured by the measuring means, and an intraocular tension calculating means for calculating intraocular tension from the Q value.

Abstract translation: 一种眼内张力测定方法，其特征在于，使用声波对要进行检查的眼球进行振动，利用非侵入性手段测定要检查的眼球的振动，求出要检查的眼球的共振的Q值，从Q测量眼内张力 值和眼内张力测量装置，包括用于振动要由声波检查的眼球的振动装置，用于非侵入性地测量要检查的眼球的振动的测量装置，用于计算谐振的Q值的Q值计算装置 根据由测量装置测量的振动来检查眼球;以及眼内张力计算装置，用于从Q值计算眼内张力。

公开(公告)号：US20080204656A1

公开(公告)日：2008-08-28

申请号：US12070323

申请日：2008-02-14

Applicant: Hiroshi Fujita ,  Toshiaki Nakagawa ,  Takayoshi Suzuki

Inventor： Hiroshi Fujita ,  Toshiaki Nakagawa ,  Takayoshi Suzuki

IPC: A61B3/14 ,  G06K9/60

CPC classification number: A61B3/14 ,  G06T7/593 ,  G06T7/85 ,  G06T2207/10012 ,  G06T2207/30041

Abstract: A model eye that models the optical characteristics of a human eye and is endowed with a grayscale pattern on the ocular fundus model surface is stereographically photographed with a parallax via a stereo photographic optical system. Photographed images are processed to provide calibration data for correcting the shape distortions of the stereo photographic optical system. The calibration data is used to correct a distortion-affected shape data and parallax images obtained in stereographic photography of the actual ocular fundus of a subject's eye. The shape distortion-corrected parallax image is used for a three-dimensional measurement process and 3D display on a stereo monitor. This allows an accurate three-dimensional measurement to be carried out and an accurate fundus image to be produced. The examiner can accurately evaluate the stereo shape of the ocular fundus of the subject's eye.

Abstract translation: 通过立体摄影光学系统立体地拍摄具有视差的模拟眼睛，其模拟人眼的光学特性并且在眼底模型表面上具有灰度图案。 处理拍摄的图像以提供用于校正立体摄影光学系统的形状失真的校准数据。 校准数据用于校正在受试者眼睛的实际眼底的立体摄影中获得的失真影响的形状数据和视差图像。 形状失真校正后的视差图像用于立体监视器上的三维测量处理和3D显示。 这允许进行准确的三维测量并且产生准确的眼底图像。 检查者可以准确评估受试者眼睛的眼底的立体形状。

公开(公告)号：US07414066B2

公开(公告)日：2008-08-19

申请号：US10985915

申请日：2004-11-09

Applicant: Kimiyuki Shibuya ,  Toru Miura ,  Katsumi Kawamine ,  Yukihiro Sato ,  Tadaaki Ohgiya ,  Takahiro Kitamura ,  Chiyoka Ozaki ,  Toshiyuki Edano ,  Mitsuteru Hirata

Inventor： Kimiyuki Shibuya ,  Toru Miura ,  Katsumi Kawamine ,  Yukihiro Sato ,  Tadaaki Ohgiya ,  Takahiro Kitamura ,  Chiyoka Ozaki ,  Toshiyuki Edano ,  Mitsuteru Hirata

IPC: A61K31/4439 ,  C07D401/12

CPC classification number: C07D403/12 ,  A61K31/4439 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D513/04

Abstract: The present invention provides to a novel compound having an ACAT inhibiting activity.The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR4—, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR5—, R4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.

Abstract translation: 本发明提供具有ACAT抑制活性的新型化合物。 本发明涉及由式（I）表示的化合物，其中表示任选取代的二价残基例如苯，吡啶，环己烷或萘，或者基团，Het表示5至8元，取代或未取代的杂环基， 至少一个选自氮原子，氧原子和硫原子的杂原子，如单环基团，多环基团或稠环基团，X表示-NH-，氧原子或硫原子 原子，Y表示-NR 4 - ，氧原子，硫原子，亚砜或砜，Z表示单键或-NR 5 - ， - R 4表示氢原子，低级烷基，芳基或任选取代的甲硅烷基低级烷基，R 5表示氢原子，低级烷基，芳基 基团或任选取代的甲硅烷基低级烷基，n为1至15的整数，或其盐或溶剂化物， d含有这些化合物中的至少一种的药物组合物。

公开(公告)号：US20080050381A1

公开(公告)日：2008-02-28

申请号：US11661260

申请日：2005-08-30

Applicant: Tsutomu Takeuchi ,  Keiko Yoshimoto

Inventor： Tsutomu Takeuchi ,  Keiko Yoshimoto

IPC: A61K39/395 ,  A61P5/00 ,  C07K16/18 ,  C12N5/06 ,  G01N33/577

CPC classification number: G01N33/68 ,  A61K2039/505 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/564 ,  G01N33/74 ,  G01N2500/00

Abstract: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody.

Abstract translation: 具有对应于人BAFF（属于TNF家族的B细胞活化因子）的134位至146位的氨基酸序列AVQGPEETVT QDC（以单字母​​氨基酸编码表示）的肽的抗体，其优选为单克隆抗体 抗体; 制备上述抗体的方法; 含有该抗体的药物组合物; 抗体的利用; 以及使用抗体筛选对BAFF的抑制作用或活化作用的方法。

公开(公告)号：US20080036967A1

公开(公告)日：2008-02-14

申请号：US11888240

申请日：2007-07-31

Applicant: Satoshi Shimada ,  Yoshikatsu Suzumura

Inventor： Satoshi Shimada ,  Yoshikatsu Suzumura

IPC: A61B3/024

CPC classification number: A61B3/024

Abstract: There is provided a perimeter that allows a reliability evaluation to be performed in a kinetic visual field examination. A stimulus for examination is displayed onto an inner surface of a visual field dome and moved at a constant speed on a meridian toward the center of the dome. A subject responds to the stimulus for examination when he visually recognized the moving stimulus. There is displayed a false-negative stimulus, which is more visible than the stimulus for examination, or a false-positive stimulus, which corresponds to the operating sound of the perimeter without any stimulus display. The visual field examination results are evaluated on the basis of a response made by the subject to the false-negative and the false-positive stimuli.This arrangement allows the reliability of the examination results in a kinetic visual field examination to be satisfactorily evaluated.

Abstract translation: 提供了允许在动态视野检查中执行可靠性评估的周界。 将检查刺激显示在视场圆顶的内表面上，并且以经度向恒定的速度移动到圆顶的中心。 当他在视觉上认识到运动刺激时，一个主体会对待检查的刺激作出反应。 显示了一种假阴性刺激，其比用于检查的刺激更可见，或者假阳性刺激，其对应于周边的操作声音而没有任何刺激显示。 视野检查结果根据受试者对假阴性和假阳性刺激的反应进行评估。 这种布置允许对动态视野检查中的检查的可靠性进行令人满意的评估。

公开(公告)号：US20080036965A1

公开(公告)日：2008-02-14

申请号：US11683632

申请日：2007-03-08

Applicant: Satoshi Shimada

Inventor： Satoshi Shimada

IPC: A61B3/14

CPC classification number: A61B3/024 ,  A61B3/12

Abstract: A perimeter is comprised of means for setting a second visual field coordinate system on a fundus image displayed on a monitor wherein an origin is a macula lutea, means for provisionally determining a blind spot position on the second visual field coordinate system, means for searching a coordinate position of a blind spot on the first visual field coordinate system by presenting a stimulus on the visual field dome, means for changing a scale of the second visual field coordinate system so as to correspond the coordinate value of the blind spot on the first visual field coordinate system and the coordinate position of the blind spot on the second visual field coordinate system with each other, and means for conducting a perimetry by presenting the stimulus at a position on the first visual field coordinate system having the same coordinate value as one on the second coordinate system of a predetermined test point.

Abstract translation: 周边包括用于在显示在监视器上的眼底图像上设置第二视野坐标系的装置，其中原点是黄斑黄斑，临时确定第二视野坐标系上的盲点位置的装置， 通过在视野圆顶上呈现刺激而将盲点的坐标位置设置在第一视场坐标系上，用于改变第二视野坐标系的刻度的装置，以便对应于第一视觉上的盲点的坐标值 场坐标系和第二视场坐标系上的盲点的坐标位置，以及用于通过在具有相同坐标值的第一视场坐标系上的位置处呈现刺激来进行视野测量的装置 预定测试点的第二坐标系。

公开(公告)号：US20070293535A1

公开(公告)日：2007-12-20

申请号：US10590492

申请日：2005-02-24

Applicant: Takahide Kohro ,  Yoshikazu Shibasaki ,  Takao Hamakubo ,  Tatsuhiko Kodama

Inventor： Takahide Kohro ,  Yoshikazu Shibasaki ,  Takao Hamakubo ,  Tatsuhiko Kodama

IPC: A61K31/47 ,  A61P9/14 ,  C07D215/00 ,  C12N5/02 ,  G01N33/53

CPC classification number: G01N33/5008 ,  C12Q1/48 ,  G01N33/5064

Abstract: A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus.

Abstract translation: 包含类异戊二烯合成抑制剂和/或香叶基香叶基转移酶抑制剂如HMG-CoA合成酶抑制剂，HMG-CoA还原酶抑制剂，AMPK活化剂或法呢基焦磷酸合成酶的Cdc42蛋白的核转移启动子; 使用; 一种方法; 包括Cdc42蛋白的核转移启动子作为活性成分的血管补救剂; 以及筛选血管补救的方法，其包括测定Cdc42蛋白转移到细胞核中的能力。